Evidence map›Paper›PMID 34589999›Full record

ArticleJTO clinical and research reports2021

Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan.

Yasushi Yatabe, Yasumasa Yoshiki, Koichi Matsumura, Kanae Togo, Hironori Kikkawa, Laura Iadeluca, Benjamin Li, Kazuto Nishio

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Yasushi YatabeDepartment of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
Yasumasa YoshikiPfizer Japan, Inc., Tokyo, Japan.
Koichi MatsumuraPfizer Japan, Inc., Tokyo, Japan.
Kanae TogoPfizer Japan, Inc., Tokyo, Japan.
Hironori KikkawaPfizer Japan, Inc., Tokyo, Japan.
Laura IadelucaPfizer Inc., New York, New York.
Benjamin LiPfizer Inc., New York, New York.
Kazuto NishioDepartment of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.
Pfizer (Japan) · JPPfizer (United States) · USKindai University · JPTokyo National Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDiagnostic testing is important in determining appropriate treatment for individuals with lung cancer. In 2018, testing of five biomarkers (

methodsThis descriptive, retrospective observational study used the Japan Medical Data Vision Co., Ltd. (MDV), database (June 2017-November 2018) and covered data for

resultsOf 8323 patients with any biomarker test, 83.2% were tested for

conclusionsThis real-world evidence revealed variations in diagnostic testing patterns, which could affect time to treatment in Japan. Variations are likely influenced by individual biomarker prioritization considering limited tissue samples in clinical practice.

Indexed as

Biomarker testingCompanion diagnosticsLung cancerReal-world data in JapanTime to treatment

Identifiers

PMID34589999
PMCPMC8474388
OpenAlexW3117492410

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.